Anti-PAK1 antibody detects endogenous levels of total PAK1 protein.
The PAK1 (p21 (RAC1) activated kinase 1) gene is mapped to human chromosome 11q13.5-q14.1. It belongs to the family of serine/threonine kinases and the gene is evolutionarily conserved.
Immunogen
The antiserum was produced against synthesized peptide derived from human PAK1.
Immunogen Range: 178-227
Biochem/physiol Actions
PAK1 (p21 (RAC1) activated kinase 1) maintains the cytoskeleton and cellular morphology. It is associated with cell cycle, cell motility, survival, and cell death. PAK1 is upregulated in different types of cancer. PAK1 is found to be involved in growth, invasion, and metastasis of cancer cells, as it affects the action of pro-apoptotic signals. In neurodegenerative diseases, such as Huntington′s disease and Alzheimer′s disease, and mental retardation, abnormal regulation of PAK1 is observed. PAK1 induces MAPK (mitogen activated protein kinase) signal pathway and cytoskeletal remodeling in breast cancer, thereby serving as an oncogene. PAK1 is known to significantly participate in the development, maturation and plasticity of the nervous system.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physical form
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Threonine 209 phosphorylation on RUNX3 by Pak1 is a molecular switch for its dualistic functions.
Kumar A
Oncogene, 35(37), 4857-4865 (2016)
Expression of p21-activated kinases 1 and 3 is altered in the brain of subjects with depression.
Fuchsova B
Neuroscience, 333, 331-344 (2016)
Down-regulation of p21-activated serine/threonine kinase 1 is involved in loss of mesencephalic dopamine neurons.
Kim H
Molecular Brain, 9(1):45, 1-13 (2016)
Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma.
Schraml P
The American Journal of Pathology, 163(3), 985-992 (2003)
MicroRNA-494 inhibits breast cancer progression by directly targeting PAK1.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
